Comparing efficacy and survivals of initial treatments for elderly patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials.

Content Provider	Europe PMC
Author	Liu, Xiaoping Chen, Jiarui He, Yuncen A Meng, Xiangyu Li, Kaili He, Colin K Liu, Shangqin
Copyright Year	2017
Abstract	ObjectiveThe aim of this study was to evaluate the efficacy and clinical outcome of initial therapies for elderly patients with multiple myeloma (MM).MethodsRandomized controlled trials (RCTs) were obtained through a comprehensive search. Response rate, progression-free survival (PFS) and overall survival (OS) were the interested outcome measures. Network meta-analysis (NMA) using graph theory methodology to construct an NMA model, and sensitivity analysis were performed.ResultsNineteen RCTs containing 7,235 participants and 17 treatments were included in the NMA. As compared to the classic melphalan plus prednisone (MP) regimen, the majority of other initial regimens showed higher rates of complete response/near complete response, overall response rate (ORR) and better PFS as well as OS. These four outcomes favored the two lenalidomide plus dexamethasone regimens (continuous lenalidomide and 18 cycles of lenalidomide plus dexamethasone), especially continuous lenalidomide plus dexamethasone regimen, over the majority of other regimens including the two established standard treatments (MP plus thalidomide or bortezomib) for elderly patients with newly diagnosed MM.ConclusionContinuous lenalidomide plus dexamethasone ranked as the best regimen in terms of ORR and OS for the treatment of elderly patients with newly diagnosed MM.
Journal	Oncotargets and Therapy
Volume Number	10
PubMed Central reference number	PMC5189699
PubMed reference number	28053546
e-ISSN	11786930
DOI	10.2147/ott.s123680
Language	English
Publisher	Dove Medical Press
Publisher Date	2016-12-22
Access Restriction	Open
Rights License	The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. © 2017 Liu et al. This work is published and licensed by Dove Medical Press Limited
Subject Keyword	multiple myeloma previously untreated elderly patients initial therapies network meta-analysis
Content Type	Text
Resource Type	Article
Subject	Pharmacology (medical) Oncology